Table of Contents
Lymphoma
Volume 2014, Article ID 160421, 6 pages
http://dx.doi.org/10.1155/2014/160421
Clinical Study

Rituximab Induced Interstitial Lung Disease in Patients with Non-Hodgkin’s Lymphoma: A Clinical Study of Six Cases and Review of the Literature

1Department of Respiratory Medicine, M. S. Ramaiah Medical College and Hospitals, MSRIT Post, Bangalore 560054, India
2Department of Medical Oncology, M. S. Ramaiah Medical College and Hospitals, MSRIT Post, Bangalore 560054, India

Received 7 July 2014; Revised 21 August 2014; Accepted 7 September 2014; Published 15 September 2014

Academic Editor: Valli De Re

Copyright © 2014 Uma Maheswari Krishnaswamy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. D. Cheson and J. P. Leonard, “Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma,” The New England Journal of Medicine, vol. 359, no. 6, pp. 613–626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. W. Friedberg, “Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy,” Hematology/The Education Program of the American Society of Hematology, vol. 2005, no. 1, pp. 329–334, 2005. View at Publisher · View at Google Scholar
  3. V. McDonald and M. Leandro, “Rituximab in non-haematological disorders of adults and its mode of action,” The British Journal of Haematology, vol. 146, no. 3, pp. 233–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Bienvenu, R. Chvetzoff, G. Salles et al., “Tumor necrosis factor α release is a major biological event associated with rituximab treatment,” Hematology Journal, vol. 2, no. 6, pp. 378–384, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Kimby, “Tolerability and safety of rituximab (MabThera),” Cancer Treatment Reviews, vol. 31, no. 6, pp. 456–473, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. V. González, E. Salgueiro, F. J. Jimeno, A. Hidalgo, T. Rubio, and G. Manso, “Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 7, pp. 714–721, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. P. R. Bauer, C. S. Zent, M.-C. Aubry, and J. H. Ryu, “Recurrent fevers, cough, and pulmonary opacities in a middle-aged man,” Chest, vol. 137, no. 6, pp. 1465–1469, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. R. Tonelli, R. Lottenberg, R. W. Allan, and P. S. Sriram, “Rituximab-induced hypersensitivity pneumonitis,” Respiration, vol. 78, no. 2, pp. 225–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Subramanian, R. Manjunath, N. Kilara, and M. K. N. Rao, “Rituximab-induced subacute interstitial pneumonitis: a case report and review of literature,” Journal of Cancer Research and Therapeutics, vol. 6, no. 3, pp. 344–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Saito, T. Nakamaki, D. Adachi, J. Suzuki, and S. Tomoyasu, “Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma,” International Journal of Hematology, vol. 80, no. 2, pp. 164–167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. R. J. Leon, A. Gonsalvo, R. Salas, and N. C. Hidalgo, “Rituximab-induced acute pulmonary fibrosis,” Mayo Clinic Proceedings, vol. 79, no. 7, pp. 949–953, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Mian, C. Rass, G. Hutarew, B. Kofler, M. Fiegl, and R. Greil, “Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature,” Leukemia and Lymphoma, vol. 47, no. 8, pp. 1683–1685, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. D. T. Alexandrescu, J. P. Dutcher, K. O'Boyle, M. Albulak, S. Oiseth, and P. H. Wiernik, “Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma,” Leukemia & Lymphoma, vol. 45, no. 11, pp. 2321–2325, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Burton, R. Kaczmarski, R. Jan-Mohamed, M. C. Benyunes, P. S. Multani, and A. Saunders, “Interstitial pneumonitis related to rituximab therapy,” The New England Journal of Medicine, vol. 348, no. 26, pp. 2690–2691, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Soubrier, G. Jeannin, J. L. Kemeny et al., “Organizing pneumonia after rituximab therapy: two cases,” Joint Bone Spine, vol. 75, no. 3, pp. 362–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. S. A. Wagner, A. C. Mehta, and D. A. Laber, “Rituximab-induced interstitial lung disease,” The American Journal of Hematology, vol. 82, no. 10, pp. 916–919, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Liote, F. Liote, B. Seroussi, C. Maynaud, and J. Cadranel, “Rituximab induced lung disease: a systematic literature review,” European Respiratory Journal, vol. 35, pp. 681–687, 2010. View at Google Scholar
  18. X. Liu, X.-N. Hong, Y.-J. Gu, B.-Y. Wang, Z.-G. Luo, and J. Cao, “Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma,” Leukemia and Lymphoma, vol. 49, no. 9, pp. 1778–1783, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Ennishi, Y. Terui, M. Yokoyama et al., “Increased incidence of interstitial pneumonia by CHOP combined with rituximab,” International Journal of Hematology, vol. 87, no. 4, pp. 393–397, 2008. View at Publisher · View at Google Scholar · View at Scopus